OriC902 / Oricell - LARVOL DELTA

A glypican-3 targeted chimeric antigen receptor T cell product secreting programmed cell death ligand 1 and vascular endothelial growth factor blockers shows durable tumor shrinkage in advanced hepatocellular carcinoma (EASL 2026) - "A GPC3 CAR-T secreting anti-PD-L1 and anti-VEGF can normalize tumor vasculature and enhance T cell trafficking, supporting a spatio-temporal delivery concept that may boost efficacy while limiting high systemic antibody exposure. Based on the "three-in-one" synergy evidence and the in vivo performance of X-CAR–process-based CAR-T cells, an investigator-initiated clinical trial of OriC902 has been initiated."

CAR T-Cell Therapy • IO biomarker • Metastases • Hepatocellular Cancer • Oncology • Solid Tumor • CD31 • GPC3 • IFNG • PD-L1 • PECAM1

Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies (PRNewswire) - "Proceeds will accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving ways to commercialization....Oricell has generated proof-of-concept (POC) clinical data across multiple pipeline CAR-T products. Its lead program, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma (HCC)....The innovative secreting CAR-T, OriC902, has shown groundbreaking efficacy and durability in ultra-late-line and difficult-to-treat solid tumor patients."

Financing • Hepatocellular Cancer